DEA moves to place O-desmethyltramadol in Schedule I [telehealth-dea]
DEA issued a notice of intent on June 24, 2026 to temporarily place O-desmethyltramadol (O-DSMT), a tramadol metabolite sold in research-chemical channels, in Schedule I along with its isomers, esters, ethers, and salts (federalregister.gov). This is a notice of intent, not the order itself: the Schedule I controls and criminal sanctions attach only when DEA issues the temporary order that follows. O-DSMT is not a peptide or a hormone, but it circulates through the same gray-market research-chemical suppliers some clinics lean on for unapproved raw materials, and the pattern is the story: DEA keeps reaching for temporary scheduling to move quickly on novel synthetics. Have whoever manages sourcing confirm no supplier on your list carries this compound or its analogs, and set a watch on the Federal Register for the temporary order's effective date.
Source: federalregister.gov (2026-06-24)

How California treats MSO structures, per DJ Holt Law [operator-intel]
DJ Holt Law published a July 1, 2026 read on California's tightening treatment of management services organizations and friendly-physician arrangements, arguing that structures set up years ago may not survive current state scrutiny (djholtlaw.com). This is a law firm's analysis of enforcement direction, not a specific action against a named clinic, but the exposure points it flags are concrete: MSO fee formulas that skim clinical revenue, non-physician owners setting clinical menus, and medical directors who supervise on paper only. A California hormone or peptide clinic running through an MSO is exactly the profile this describes. Have your healthcare counsel re-paper the MSO agreement and confirm the physician entity actually controls hiring, protocols, and clinical revenue, and treat that review as a gating item before your next expansion, not a cleanup task after.
Source: djholtlaw.com (2026-07-01)

FTC finalizes order barring Rollins from enforcing noncompetes against 18,000 workers [operator-intel]
The FTC approved a final consent order on June 22, 2026 requiring Rollins Inc., one of the largest pest-control companies in the country, to stop enforcing noncompete agreements against more than 18,000 employees nationwide (ftc.gov). The compound is pest control, but the mechanism is what matters to any multi-site clinic operator: the FTC is still treating overbroad noncompetes as an enforcement target and willing to finalize orders against them, whatever the broader status of its rulemaking. If your prescriber and nurse-injector contracts lean on wide noncompetes to hold staff, that hold is worth less than it was, and an aggressive clause can become the liability instead of the protection. Have employment counsel audit your clinical-staff agreements for enforceability in each state you operate, and price your retention on compensation and equity rather than on a clause a regulator may not let you enforce.
Source: ftc.gov (2026-06-22)

Florida Board of Nursing clarifies RN injection authority for med spas [operator-intel]
Lengea Law flagged a Florida Board of Nursing declaratory statement (DOH-24-0637) that reinforces a standard many med spas may not be meeting: when a registered nurse administers aesthetic injections, a licensed physician must be physically present with direct visual observation of the injection (lengealaw.com). This is a state board reading of existing rules, secondary to the declaratory statement itself, but the operational hit lands on any Florida clinic that built its injectable workflow around remote or after-the-fact physician oversight. Hormone and peptide clinics that fold aesthetics into the same room inherit the same supervision standard. Confirm with your Florida medical director whether your injection room meets the physical-presence and direct-observation test, and read the declaratory statement itself before you rely on how a vendor summarized it.
Source: lengealaw.com (2026-06-30)

Wedgewood Pharmacy applies to import controlled substances [compounding-bulks]
DEA published a notice on June 17, 2026 that Wedgewood Pharmacy LLC has applied for registration as an importer of controlled substances (federalregister.gov). This is an application, not a grant: nothing about who imports what changes until DEA completes its review, and the notice opens a window, typically 30 days, for existing registrants to comment. Wedgewood is a large compounding supplier, so the drug classes named in the notice's supplementary information are the part to read, since shifts in a major compounder's import posture can ripple into API availability and lead times downstream. This is a supply-chain and counterparty signal, not a change to which substances a clinic may compound. If your pharmacy relationships touch Wedgewood or the classes listed, pull the notice, check the substances against your sourcing, and ask your compounding partners where their bulk API originates.
Source: federalregister.gov (2026-06-17)

Put the "Riders on the Storm" series in front of your regulatory counsel and ask which FY2027 report directives touch your compounding or GLP-1 sourcing.

Confirm no supplier on your list carries O-desmethyltramadol or its analogs before the DEA temporary order lands.

Start the countdown to the PCAC advisory meeting on July 23-24: it is 20 days out, and staff-briefing materials post no later than two business days before.

If you run a California clinic through an MSO, book the counsel review now rather than after your next lease signs.

Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I (2026-06-24, federalregister.gov)

FTC Approves Final Consent Order in Pest-Control Noncompete Matter (2026-06-22, ftc.gov)

Importer of Controlled Substances Application: Wedgewood Pharmacy LLC (2026-06-17, federalregister.gov)

PCAC advisory meeting set for July 23-24, 2026 on seven peptides for the 503A bulks list (Federal Register 2026-07361, published 2026-04-16; docket FDA-2025-N-6895). Advisory recommendation only; FDA decides through rulemaking.

Riders on the Storm Part 3: Devices, Compounding, GLP-1 Medications, and Food (thefdalawblog.com)

How California Treats MSO Structures (djholtlaw.com)

Florida Board of Nursing Clarifies RN Injection Authority (lengealaw.com)

None today.